Protagonist Therapeutics, Inc

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

PTGX$136.26+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)


· · Three Months Ended · · Six Months Ended
· · June 30, · · June 30,
· · 2026 · · 2025 · · 2026 · · 2025
License and collaboration revenue	$213,475	$5,546	$269,843	$33,867
Operating expenses:
Research and development	42,061	37,036	88,800	72,929
General and administrative	12,648	10,551	25,925	22,289
Total operating expenses	54,709	47,587	114,725	95,218
Income (loss) from operations	158,766	(42,041)	155,118	(61,351)
Interest income	6,429	7,406	12,305	14,979
Other (expense) income, net	(81)	36	(28)	118
Income (loss) before income tax expense	165,114	(34,599)	167,395	(46,254)
Income tax expense	2,265	172	763	172
Net income (loss)	$162,849	$(34,771)	$166,632	$(46,426)
Net income (loss) per share, basic	$2.47	$(0.55)	$2.54	$(0.73)
Net income (loss) per share, diluted	$2.29	$(0.55)	$2.35	$(0.73)
Weighted-average shares used to compute net income (loss) per share, basic	65,935,769	63,510,537	65,514,150	63,238,682
Weighted-average shares used to compute net income (loss) per share, diluted	71,007,011	63,510,537	70,818,718	63,238,682

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.